Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19-9 undergoing pancreatic ductal adenocarcinoma resection
{{output}}
Background: Serum Ca 19-9 is the most widely used biomarker in pancreatic ductal adenocarcinoma (PDAC). This study assessed the link between preoperative Ca 19-9, neoadjuvant chemotherapy (ChTNeo), and outcomes after pancreatic r... ...
